Intensive BP target reduces LVH rates, increases LVH regression
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Targeting a systolic BP (SBP) of <120 mmHg among patients with hypertension without diabetes is associated with reduced rates of left ventricular hypertrophy (LVH) and increased rates of LVH regression.
Why this matters
This analysis from the SPRINT trial focuses on LVH, an important marker of end-organ damage and common in hypertension.
A previous analysis of data from the ACCORD trial showed benefits of <120 mmHg targets for patients with diabetes and hypertension, they had a reduced risk for LVH as well.
Secondary analysis of 8164 participants with hypertension but without diabetes randomly assigned to intensive (target SBP, <120 mmHg) or standard (target SBP, <140 mmHg) BP lowering arms in SPRINT trial.
Funding: SPRINT funded by NIH, Department of Veterans Affairs, and others.
Median follow-up period was 3.81 y.
In participants without baseline LVH (n=7559), intensive vs standard arm was associated with lower risk of developing LVH (HR, 0.54; P<.001).
In participants with baseline LVH (n=605), those assigned to intensive arm were more likely to regress vs standard arm (HR, 1.66; P<.001).